Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ezetimibe.

Malcolm J M Darkes1, Raewyn M Poole, Karen L Goa

  • 1Adis International Inc., Langhorne, Pennsylvania, USA.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|January 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Maclobemide.

Drugs·2017
Same author

Erratum to: Moclobemide.

Drugs·2017
Same author

Erratum to: Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders.

Drugs·2017
Same author

Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study.

Neurology and therapy·2015
Same author

Pembrolizumab: first global approval.

Drugs·2014
Same author

Eliglustat: first global approval.

Drugs·2014
Same journal

GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Clinical Pharmacology of Plozasiran.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Correction: Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Comment on "Polypill Strategy: A Paradigm Shift in Cardiovascular Disease Prevention".

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Spironolactone or Finerenone for Cardiovascular and Kidney Protection in Patients with Moderate CKD?

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
See all related articles

Ezetimibe effectively lowers LDL cholesterol by inhibiting intestinal absorption. When combined with statins, it enhances lipid-lowering effects and is well-tolerated, offering a valuable treatment option for hypercholesterolemia.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Ezetimibe is a novel synthetic 2-azetidinone that selectively inhibits cholesterol absorption.
  • It targets a putative cholesterol transporter in the small intestine's enterocyte brush-border membrane.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of ezetimibe as monotherapy and in combination with statins for managing dyslipidemia.

Main Methods:

  • Large, randomized, placebo-controlled, and double-blind clinical trials.
  • Assessment of lipid profiles (LDL-C, triglycerides, HDL-C) in patients receiving ezetimibe alone or with statins.
  • Evaluation of tolerability and adverse event profiles.

Main Results:

  • Ezetimibe monotherapy reduced LDL-C by approximately 18% and modestly increased HDL-C.

Related Experiment Videos

  • Combination therapy with statins yielded greater reductions in LDL-C and triglycerides compared to statin monotherapy.
  • Ezetimibe demonstrated efficacy in patients with homozygous familial hypercholesterolemia and homozygous sitosterolemia.
  • Ezetimibe exhibited a similar tolerability profile to placebo, and coadministration with statins did not increase adverse events.

    • Conclusions:

    • Ezetimibe is an effective agent for lowering LDL-C and improving lipid profiles.
    • Combination therapy with ezetimibe and statins offers enhanced lipid-lowering benefits.
    • Ezetimibe is well-tolerated and represents a valuable therapeutic option for hypercholesterolemia management.